Deal watch: IL-2 focus switches to stimulating Tregs,Nature Reviews Drug Discovery

当前位置： X-MOL 学术 › Nat. Rev. Drug. Disc. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Deal watch: IL-2 focus switches to stimulating Tregs
Nature Reviews Drug Discovery ( IF 120.1 ) Pub Date : 2017-09-01 , DOI: 10.1038/nrd.2017.171
Megan Cully

Recombinant interleukin-2 (IL-2) has been used since the early 1990s for the treatment of renal cell carcinoma and melanoma, as high-dose IL-2 has immune-stimulating properties. A spate of deals in 2017 — including Eli Lilly's acquisition of co-development rights to Nektar's NKTR-358, the acquisition

中文翻译：